236 related articles for article (PubMed ID: 25529192)
1. Pharmacokinetic, pharmacodynamic and biomarker evaluation of transforming growth factor-β receptor I kinase inhibitor, galunisertib, in phase 1 study in patients with advanced cancer.
Rodón J; Carducci M; Sepulveda-Sánchez JM; Azaro A; Calvo E; Seoane J; Braña I; Sicart E; Gueorguieva I; Cleverly A; Pillay NS; Desaiah D; Estrem ST; Paz-Ares L; Holdhoff M; Blakeley J; Lahn MM; Baselga J
Invest New Drugs; 2015 Apr; 33(2):357-70. PubMed ID: 25529192
[TBL] [Abstract][Full Text] [Related]
2. First-in-human dose study of the novel transforming growth factor-β receptor I kinase inhibitor LY2157299 monohydrate in patients with advanced cancer and glioma.
Rodon J; Carducci MA; Sepulveda-Sánchez JM; Azaro A; Calvo E; Seoane J; Braña I; Sicart E; Gueorguieva I; Cleverly AL; Pillay NS; Desaiah D; Estrem ST; Paz-Ares L; Holdhoff M; Blakeley J; Lahn MM; Baselga J
Clin Cancer Res; 2015 Feb; 21(3):553-60. PubMed ID: 25424852
[TBL] [Abstract][Full Text] [Related]
3. Clinical development of galunisertib (LY2157299 monohydrate), a small molecule inhibitor of transforming growth factor-beta signaling pathway.
Herbertz S; Sawyer JS; Stauber AJ; Gueorguieva I; Driscoll KE; Estrem ST; Cleverly AL; Desaiah D; Guba SC; Benhadji KA; Slapak CA; Lahn MM
Drug Des Devel Ther; 2015; 9():4479-99. PubMed ID: 26309397
[TBL] [Abstract][Full Text] [Related]
4. Phase 1 study of galunisertib, a TGF-beta receptor I kinase inhibitor, in Japanese patients with advanced solid tumors.
Fujiwara Y; Nokihara H; Yamada Y; Yamamoto N; Sunami K; Utsumi H; Asou H; TakahashI O; Ogasawara K; Gueorguieva I; Tamura T
Cancer Chemother Pharmacol; 2015 Dec; 76(6):1143-52. PubMed ID: 26526984
[TBL] [Abstract][Full Text] [Related]
5. Biomarker and Histopathology Evaluation of Patients with Recurrent Glioblastoma Treated with Galunisertib, Lomustine, or the Combination of Galunisertib and Lomustine.
Capper D; von Deimling A; Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Estrem ST; Lahn MM; Wick W
Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28481241
[TBL] [Abstract][Full Text] [Related]
6. Cardiac Safety of TGF-β Receptor I Kinase Inhibitor LY2157299 Monohydrate in Cancer Patients in a First-in-Human Dose Study.
Kovacs RJ; Maldonado G; Azaro A; Fernández MS; Romero FL; Sepulveda-Sánchez JM; Corretti M; Carducci M; Dolan M; Gueorguieva I; Cleverly AL; Pillay NS; Baselga J; Lahn MM
Cardiovasc Toxicol; 2015 Oct; 15(4):309-23. PubMed ID: 25488804
[TBL] [Abstract][Full Text] [Related]
7. Galunisertib (LY2157299), a transforming growth factor-β receptor I kinase inhibitor, attenuates acute pancreatitis in rats.
Liu X; Yu M; Chen Y; Zhang J
Braz J Med Biol Res; 2016 Aug; 49(9):e5388. PubMed ID: 27509307
[TBL] [Abstract][Full Text] [Related]
8. Anti-tumor activity of the TGF-β receptor kinase inhibitor galunisertib (LY2157299 monohydrate) in patient-derived tumor xenografts.
Maier A; Peille AL; Vuaroqueaux V; Lahn M
Cell Oncol (Dordr); 2015 Apr; 38(2):131-44. PubMed ID: 25573078
[TBL] [Abstract][Full Text] [Related]
9. A Phase II randomized study of galunisertib monotherapy or galunisertib plus lomustine compared with lomustine monotherapy in patients with recurrent glioblastoma.
Brandes AA; Carpentier AF; Kesari S; Sepulveda-Sanchez JM; Wheeler HR; Chinot O; Cher L; Steinbach JP; Capper D; Specenier P; Rodon J; Cleverly A; Smith C; Gueorguieva I; Miles C; Guba SC; Desaiah D; Lahn MM; Wick W
Neuro Oncol; 2016 Aug; 18(8):1146-56. PubMed ID: 26902851
[TBL] [Abstract][Full Text] [Related]
10. TGFβR1 Blockade with Galunisertib (LY2157299) Enhances Anti-Neuroblastoma Activity of the Anti-GD2 Antibody Dinutuximab (ch14.18) with Natural Killer Cells.
Tran HC; Wan Z; Sheard MA; Sun J; Jackson JR; Malvar J; Xu Y; Wang L; Sposto R; Kim ES; Asgharzadeh S; Seeger RC
Clin Cancer Res; 2017 Feb; 23(3):804-813. PubMed ID: 27756784
[TBL] [Abstract][Full Text] [Related]
11. Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma.
Wick A; Desjardins A; Suarez C; Forsyth P; Gueorguieva I; Burkholder T; Cleverly AL; Estrem ST; Wang S; Lahn MM; Guba SC; Capper D; Rodon J
Invest New Drugs; 2020 Oct; 38(5):1570-1579. PubMed ID: 32140889
[TBL] [Abstract][Full Text] [Related]
12. A Phase 2 Study of Galunisertib (TGF-β1 Receptor Type I Inhibitor) and Sorafenib in Patients With Advanced Hepatocellular Carcinoma.
Kelley RK; Gane E; Assenat E; Siebler J; Galle PR; Merle P; Hourmand IO; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Faivre S; Benhadji KA; Giannelli G
Clin Transl Gastroenterol; 2019 Jul; 10(7):e00056. PubMed ID: 31295152
[TBL] [Abstract][Full Text] [Related]
13. Disposition and metabolism of [
Cassidy KC; Gueorguieva I; Miles C; Rehmel J; Yi P; Ehlhardt WJ
Xenobiotica; 2018 Apr; 48(4):382-399. PubMed ID: 28436712
[TBL] [Abstract][Full Text] [Related]
14. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
Harding JJ; Do RK; Yaqubie A; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Benhadji KA; Kelley RK; Abou-Alfa GK
Cancer Med; 2021 May; 10(9):3059-3067. PubMed ID: 33811482
[TBL] [Abstract][Full Text] [Related]
15. Phase I and pharmacokinetic/pharmacodynamic study of RO5126766, a first-in-class dual Raf/MEK inhibitor, in Japanese patients with advanced solid tumors.
Honda K; Yamamoto N; Nokihara H; Tamura Y; Asahina H; Yamada Y; Suzuki S; Yamazaki N; Ogita Y; Tamura T
Cancer Chemother Pharmacol; 2013 Sep; 72(3):577-84. PubMed ID: 23860959
[TBL] [Abstract][Full Text] [Related]
16. Extracellular miRNA-21 as a novel biomarker in glioma: Evidence from meta-analysis, clinical validation and experimental investigations.
Qu K; Lin T; Pang Q; Liu T; Wang Z; Tai M; Meng F; Zhang J; Wan Y; Mao P; Dong X; Liu C; Niu W; Dong S
Oncotarget; 2016 Jun; 7(23):33994-4010. PubMed ID: 27166186
[TBL] [Abstract][Full Text] [Related]
17. Design, 3D QSAR modeling and docking of TGF-β type I inhibitors to target cancer.
Ajay Kumar TV; Athavan AAS; Loganathan C; Saravanan K; Kabilan S; Parthasarathy V
Comput Biol Chem; 2018 Oct; 76():232-244. PubMed ID: 30077902
[TBL] [Abstract][Full Text] [Related]
18. A phase 1b study of transforming growth factor-beta receptor I inhibitor galunisertib in combination with sorafenib in Japanese patients with unresectable hepatocellular carcinoma.
Ikeda M; Morimoto M; Tajimi M; Inoue K; Benhadji KA; Lahn MMF; Sakai D
Invest New Drugs; 2019 Feb; 37(1):118-126. PubMed ID: 29995286
[TBL] [Abstract][Full Text] [Related]
19. NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC.
Cao Y; Agarwal R; Dituri F; Lupo L; Trerotoli P; Mancarella S; Winter P; Giannelli G
Cell Death Dis; 2017 Feb; 8(2):e2634. PubMed ID: 28230858
[TBL] [Abstract][Full Text] [Related]
20. Differential Inhibition of the TGF-β Signaling Pathway in HCC Cells Using the Small Molecule Inhibitor LY2157299 and the D10 Monoclonal Antibody against TGF-β Receptor Type II.
Dituri F; Mazzocca A; Fernando J; Peidrò FJ; Papappicco P; Fabregat I; De Santis F; Paradiso A; Sabbà C; Giannelli G
PLoS One; 2013; 8(6):e67109. PubMed ID: 23826206
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
